To evaluate the efficacy and safety of azithromycin given chronically for the treatment of
Mycobacterium avium (MAC) bacteremia in patients failing or intolerant of current available
Patients must have:
- Disseminated MAC as defined by current (within the last month) positive blood, bone
marrow, or liver biopsy culture for MAC, and considered symptomatic (fever, night
sweats, anorexia, weight loss, fatigue, or malaise).
- At least 2 months of prior treatment with available combination MAC therapy or less
than 2 months of such accompanied by unacceptable adverse effects.
- Life expectancy of more than 2 weeks.
- Approval of eligibility from Pfizer Clinical Monitor.
- Consent of parent or guardian if under legal age of consent.
- Patients who have completed acute treatment with azithromycin for MAC in protocol
066-131 or 066-148 will be exempt from inclusion criteria 1 and 2 and can continue
therapy through this protocol if their physician feels they have benefitted from
prior azithromycin therapy.
Patients with the following symptoms and conditions are excluded:
- Known hypersensitivity or intolerance to macrolide antibiotics.
- Inability to take oral medications or current condition that is likely to interfere
with absorption (e.g., gastrectomy).
- Other MAC therapy instituted during the first 2 months of the study.
- Other investigational drugs, with the exception of those available through a
Treatment IND program.
Patients with the following prior conditions are excluded:
History of hypersensitivity or intolerance to azithromycin.
- Other investigational drugs within 7 days of enrollment, with the exception of
Treatment IND drugs (such as ddC).